{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:26Z","timestamp":1788013346983,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1140701C"],"award-info":[{"award-number":["TCVGH-1140701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-NHRI113003"],"award-info":[{"award-number":["TCVGH-NHRI113003"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-YM1140115"],"award-info":[{"award-number":["TCVGH-YM1140115"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01209-0","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:32:07Z","timestamp":1773757927000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study"],"prefix":"10.1007","volume":"21","author":[{"given":"Yin-Che","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsien","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-0368","authenticated-orcid":false,"given":"Chieh\u2010Lin Jerry","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"2","key":"1209_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","volume":"99","author":"CH Tang","year":"2020","unstructured":"Tang CH, Hou HA, Huang KC, Qiu H, Liu Y. Treatment evolution and improved survival in multiple myeloma in Taiwan. Ann Hematol. 2020;99(2):321\u201330. https:\/\/doi.org\/10.1007\/s00277-019-03858-w.","journal-title":"Ann Hematol"},{"issue":"1","key":"1209_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10787-5","volume":"23","author":"C Eisfeld","year":"2023","unstructured":"Eisfeld C, Kajuter H, Moller L, Wellmann I, Shumilov E, Stang A. Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer. 2023;23(1):317. https:\/\/doi.org\/10.1186\/s12885-023-10787-5.","journal-title":"BMC Cancer"},{"issue":"10272","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5.","journal-title":"Lancet"},{"issue":"1","key":"1209_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01818-6","volume":"10","author":"L Xu","year":"2024","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024;10(1):55. https:\/\/doi.org\/10.1038\/s41420-024-01818-6.","journal-title":"Cell Death Discov"},{"issue":"6","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727\u201338. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09241.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41591-023-02528-9","volume":"26","author":"Z Wang","year":"2025","unstructured":"Wang Z, Song Y, Guo H, Yan Y, Ma L, Liu B. Targets selection for precision therapy of relapsed\/refractory multiple myeloma: the latest advancements. Curr Treat Options Oncol. 2025;26(2):128\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"1209_CR7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"6","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"1","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3324\/haematol.2024.285768","volume":"110","author":"A Visram","year":"2025","unstructured":"Visram A, Chan KK, Seow H, Pond G, Gayowsky A, Mohyuddin GR, et al. Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica. 2025;110(1):228\u201333. https:\/\/doi.org\/10.3324\/haematol.2024.285768.","journal-title":"Haematologica"},{"issue":"10","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"issue":"1","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158\u2013158. https:\/\/doi.org\/10.1038\/s41408-024-01139-y.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65(5):660\u20138. https:\/\/doi.org\/10.1080\/10428194.2024.2313628.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004.","journal-title":"Value Health"},{"issue":"14","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-cell characteristics impact response and resistance to TcCell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30(14):3006\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3333.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30(3):308.e1-13. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016.","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","volume":"9","author":"A Kowalski","year":"2025","unstructured":"Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv. 2025;9(19):4979\u201386. https:\/\/doi.org\/10.1182\/bloodadvances.2025016911.","journal-title":"Blood Adv"},{"issue":"7","key":"1209_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132","volume":"8","author":"C Korst","year":"2024","unstructured":"Korst C, Groen K, Bosman PWC, van der Valk F, Verkleij CPM, Kruyswijk S, et al. Prophylactic Tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with Teclistamab: implications for outpatient step-up dosing. Hemasphere. 2024;8(7):e132. https:\/\/doi.org\/10.1002\/hem3.132.","journal-title":"Hemasphere"},{"issue":"1","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116. https:\/\/doi.org\/10.1038\/s41408-023-00879-7.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.3324\/haematol.2025.287351","volume":"110","author":"MR Cochran-Perez","year":"2025","unstructured":"Cochran-Perez MR, Sharma P, Delisle JS, Schlesinger M, Rao H, Trias J, et al. Bispecific antibody therapy-associated opportunistic infections: cytomegalovirus retinitis and chronic salmonellosis in a non-HIV patient. Haematologica. 2025;110(11):2855\u20138. https:\/\/doi.org\/10.3324\/haematol.2025.287351.","journal-title":"Haematologica"},{"issue":"25","key":"1209_CR20","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1706640.","journal-title":"N Engl J Med"},{"key":"1209_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721998124","volume":"12","author":"PH Li","year":"2021","unstructured":"Li PH, Lin CH, Lin YH, Chen TC, Hsu CY, Teng CJ. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2021;12:2040620721998124. https:\/\/doi.org\/10.1177\/2040620721998124.","journal-title":"Ther Adv Hematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01209-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:55Z","timestamp":1774630675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01209-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chieh-Lin Jerry Teng received honoraria and consulting fees from Novartis, Roche, Pfizer, Takeda, Johnson and Johnson, Amgen, BMS Celgene, TTY, and MSD. Yin-Che Wang, Po-Hsien Li, Cheng-Hsien Lin, and Yu-Chen Su have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Participant details were de-identified, and study was conducted according to the current version of the Declaration of Helsinki. The Institutional Review Board of Taichung Veterans General Hospital approved the study (CE251005A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The Institutional Review Board of Taichung Veterans General Hospital agreed to waive the requirement for obtaining informed consent from the participants because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Y-CW:\u00a0conceptualization, methodology, investigation, writing (review and editing). P-HL: conceptualization, methodology, investigation. C-HL:\u00a0conceptualization, investigation, formal analysis, writing (review and editing).\u00a0Y-CS:\u00a0methodology, investigation, writing (review and editing).\u00a0C\u2010LJT: conceptualization, supervision, writing (review and editing). All authors gave final approval of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}